Payment overview · 2025
General Payments
$918.16
50 reported records · 20 companies
Healthcare provider profile · identity verified
Jan D Rasnake, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WYTHEVILLE, VA · NPI 1356651897
Verified facts
What the public records show
CMS Open Payments records show Jan D Rasnake, FNP received $918.16 in general payments during 2025 across 50 reported records.
Novo Nordisk Inc accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.48 | 18.4% | 12 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $117.66 | 12.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.00 | 10.9% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.63 | 7.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.00 | 7.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.66 | 4.9% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $40.53 | 4.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.24 | 4.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.68 | 3.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $30.64 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.95 | 3.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.22 | 3.0% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $24.92 | 2.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.53 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.95 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.46 | 1.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.13 | 1.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.78 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.30 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $918.16 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $117.66 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.63 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.37 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.37 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.45 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.45 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.26 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.66 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.66 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $40.53 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.68 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $30.64 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $29.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.93 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.22 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.22 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 57 |
| Gabapentin | Gabapentin | 184 | 38 |
| Lisinopril | Lisinopril | 157 | 48 |
| Famotidine | Famotidine | 145 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 38 |
| Prednisone | Prednisone | 124 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 55 |
| Tramadol Hcl | Tramadol Hcl | 111 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 109 | 33 |
| Farxiga | Dapagliflozin Propanediol | 107 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 32 |
| Furosemide | Furosemide | 103 | 37 |
| Losartan Potassium | Losartan Potassium | 96 | 32 |
| Omeprazole | Omeprazole | 96 | 32 |
| Pregabalin | Pregabalin | 93 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 67 |
| Ezetimibe | Ezetimibe | 78 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 24 |
| Trazodone Hcl | Trazodone Hcl | 73 | 23 |
| Metformin Hcl | Metformin Hcl | 71 | 21 |
| Clonazepam | Clonazepam | 70 | 11 |
| Montelukast Sodium | Montelukast Sodium | 65 | 23 |
| Potassium Chloride | Potassium Chloride | 63 | 24 |
| Eliquis | Apixaban | 61 | 14 |
| Meloxicam | Meloxicam | 61 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 24 |
| Lorazepam | Lorazepam | 59 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Ozempic | Semaglutide | 54 | 14 |
| Sertraline Hcl | Sertraline Hcl | 53 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 12 |
| Levofloxacin | Levofloxacin | 51 | 35 |
| Metformin Hcl Er | Metformin Hcl | 51 | 14 |
| Fluconazole | Fluconazole | 45 | 29 |
| Glimepiride | Glimepiride | 45 | 18 |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 24 |
| Cephalexin | Cephalexin | 43 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 28 |
| Jardiance | Empagliflozin | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 12 |
| Carvedilol | Carvedilol | 37 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 36 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Buspirone Hcl | Buspirone Hcl | 34 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Nystatin | Nystatin | 29 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Methocarbamol | Methocarbamol | 27 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Atenolol | Atenolol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $918.16 · 50 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, Azstarys, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, FASENRA, FREESTYLE LIBRE 3, HETLIOZ, IBSRELA, INSPIRE, Jornay PM, LINZESS, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Sunosi, UBRELVY, Wegovy, XHANCE, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error